Strs Ohio Has $21.80 Million Stake in Elevance Health, Inc. $ELV

Strs Ohio lowered its position in shares of Elevance Health, Inc. (NYSE:ELV) by 3.8% during the first quarter, HoldingsChannel reports. The fund owned 74,469 shares of the company’s stock after selling 2,938 shares during the quarter. Strs Ohio’s holdings in Elevance Health were worth $21,801,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of ELV. Kemnay Advisory Services Inc. bought a new stake in shares of Elevance Health during the fourth quarter worth about $31,000. J.Safra Asset Management Corp bought a new position in Elevance Health in the 4th quarter valued at approximately $32,000. ORG Partners LLC raised its holdings in Elevance Health by 120.4% in the 4th quarter. ORG Partners LLC now owns 108 shares of the company’s stock valued at $38,000 after buying an additional 59 shares during the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new stake in Elevance Health during the 4th quarter worth approximately $38,000. Finally, Dorato Capital Management acquired a new stake in Elevance Health during the 4th quarter worth approximately $41,000. Institutional investors and hedge funds own 89.24% of the company’s stock.

Insider Buying and Selling

In other news, Director Robert L. Dixon, Jr. sold 151 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $401.77, for a total transaction of $60,667.27. Following the completion of the sale, the director owned 10,734 shares in the company, valued at $4,312,599.18. The trade was a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 0.34% of the company’s stock.

Elevance Health Price Performance

ELV stock opened at $416.97 on Friday. The firm has a market cap of $90.55 billion, a price-to-earnings ratio of 17.74, a PEG ratio of 2.37 and a beta of 0.67. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $427.19. The company’s fifty day simple moving average is $391.29 and its 200 day simple moving average is $351.14.

Elevance Health (NYSE:ELV) last released its earnings results on Wednesday, April 22nd. The company reported $12.58 EPS for the quarter, topping the consensus estimate of $10.74 by $1.84. The business had revenue of $49.49 billion during the quarter, compared to analysts’ expectations of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The firm’s revenue was up 1.5% on a year-over-year basis. During the same quarter last year, the firm posted $11.97 earnings per share. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, analysts expect that Elevance Health, Inc. will post 26.86 earnings per share for the current year.

Elevance Health Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th were paid a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a yield of 1.6%. The ex-dividend date of this dividend was Wednesday, June 10th. Elevance Health’s dividend payout ratio (DPR) is 29.26%.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on ELV shares. Jefferies Financial Group dropped their price target on shares of Elevance Health from $395.00 to $391.00 and set a “buy” rating for the company in a research note on Monday, April 20th. Weiss Ratings upgraded Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, May 18th. Mizuho increased their price objective on Elevance Health from $435.00 to $465.00 and gave the company an “outperform” rating in a report on Monday, June 8th. The Goldman Sachs Group lifted their target price on Elevance Health from $350.00 to $370.00 and gave the stock a “neutral” rating in a report on Friday, April 24th. Finally, Deutsche Bank Aktiengesellschaft upgraded Elevance Health from a “hold” rating to a “buy” rating and upped their price target for the company from $363.00 to $498.00 in a research report on Wednesday, May 20th. Fourteen research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, Elevance Health has an average rating of “Moderate Buy” and a consensus price target of $419.16.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.